13F filer · CIK 1652044 ↗
Alphabet Inc.
You are looking at Q4 2018. See the latest, Q2 2026 →
Reported value
$845.8M
−19% on the quarter before
Positions
17
2 new · 2 sold out
Top 10
94.8%
of the value
Est. gain
−$116.8M
on stocks held all quarter
Est. return
−12.2%
on those stocks since Q3 2018
Positions as of Dec 31, 2018, from Alphabet Inc.'s 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q3 2018. Striped tiles are options.
Largest buys
Since Q3 2018, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Dexcom Inc~$3.3MNew · 0.0% → 0.4%+110,457 shares
- Block~$692,000New · 0.0% → 0.1%+12,342 shares
Largest sells
Since Q3 2018, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
Holdings
As of Dec 31, 2018. Changes are in shares against Sep 30, 2018, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jd Com IncSPON ADR CL A · shares 0% · price −19.8% | 33.5% | $283.7M | −$69.9M | ||||||||
| Arris Intl IncSHS · shares −22% · price +17.6% | 27.5% | $232.4M | +$34.8M | ||||||||
| Svmk IncCOM · shares 0% · price −23.5% | 6.7% | $56.5M | −$17.3M | ||||||||
| Arcus Biosciences IncCOM · shares 0% · price −22.7% | 6.4% | $54.4M | −$16.0M | ||||||||
| DocuSignCOM · shares −20% · price −23.8% | 5.6% | $46.9M | −$14.6M | ||||||||
| ZscalerCOM · shares −18% · price −3.8% | 5.5% | $46.6M | −$1.9M | ||||||||
| Forty Seven IncCOM · shares 0% · price +5.4% | 2.9% | $24.3M | +$1.2M | ||||||||
| Autolus Therapeutics PlcSPON ADS · shares 0% · price +7.1% | 2.8% | $23.4M | +$1.5M | ||||||||
| Magenta Therapeutics IncCOM · shares 0% · price −52.5% | 2.3% | $19.0M | −$21.1M | ||||||||
| SnapCL A · shares 0% · price −35.0% | 1.7% | $14.4M | −$7.8M | ||||||||
| Gritstone Oncology IncCOM · shares 0% · price +8.5% | 1.7% | $14.4M | +$1.1M | ||||||||
| Evelo Biosciences IncCOM · shares 0% · price +6.8% | 1.6% | $13.8M | +$880,000 | ||||||||
| Spero Therapeutics IncCOM · shares 0% · price −41.5% | 0.81% | $6.8M | −$4.8M | ||||||||
| Cloudera IncCOM · shares 0% · price −37.3% | 0.56% | $4.7M | −$2.8M | ||||||||
| Dexcom IncCOM · shares New | 0.39% | $3.3M | — | ||||||||
| BlockCL A · shares New | 0.08% | $692,000 | — | ||||||||
| Dropbox IncCL A · shares 0% · price −24.0% | 0.03% | $266,000 | −$84,000 | ||||||||
| Total · 17 positions | 100% | $845.8M | −$116.8M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q3 2018 to Q4 2018: 15 stocks held throughout, down $116.8M (−12.2%).
- Arris Intl Inc+$34.8M+18%
- Autolus Therapeutics Plc+$1.5M+7%
- Forty Seven Inc+$1.2M+5%
- Gritstone Oncology Inc+$1.1M+8%
- Evelo Biosciences Inc+$880,000+7%
- DocuSign−$14.6M−24%
- Arcus Biosciences Inc−$16.0M−23%
- Svmk Inc−$17.3M−23%
- Magenta Therapeutics Inc−$21.1M−53%
- Jd Com Inc−$69.9M−20%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 7, 2026 | $99.08B+2,367% | SEC ↗ |
| Q1 2026 | May 8, 2026 | $4.02B+56% | SEC ↗ |
| Q4 2025 | Feb 13, 2026 | $2.58B+7% | SEC ↗ |
| Q3 2025 | Nov 7, 2025 | $2.41B+13% | SEC ↗ |
| Q2 2025 | Aug 1, 2025 | $2.14B+35% | SEC ↗ |
| Q1 2025 | May 2, 2025 | $1.58B−8% | SEC ↗ |
| Q4 2024 | Feb 7, 2025 | $1.72B−7% | SEC ↗ |
| Q3 2024 | Nov 8, 2024 | $1.84B−7% | SEC ↗ |
| Q2 2024 | Aug 2, 2024 | $1.97B−21% | SEC ↗ |
| Q1 2024 | May 3, 2024 | $2.51B+17% | SEC ↗ |
| Q4 2023 | Feb 9, 2024 | $2.16B+39% | SEC ↗ |
| Q3 2023 | Nov 13, 2023 | $1.56B−16% | SEC ↗ |
| Q2 2023 | Aug 4, 2023 | $1.86B+3% | SEC ↗ |
| Q1 2023 | May 11, 2023 | $1.80B+5% | SEC ↗ |
| Q4 2022 | Feb 14, 2023 | $1.72B−12% | SEC ↗ |
| Q3 2022 | Nov 15, 2022 | $1.96B+6% | SEC ↗ |
| Q2 2022 | Nov 15, 2022 | $1.84B−40% | SEC ↗ |
| Q1 2022 | Nov 15, 2022 | $3.08B−26% | SEC ↗ |
| Q4 2021 | Nov 15, 2022 | $4.14B−2% | SEC ↗ |
| Q3 2021 | Nov 15, 2022 | $4.22B−14% | SEC ↗ |
| Q2 2021 | Nov 15, 2022 | $4.91B+98% | SEC ↗ |
| Q1 2021 | Nov 15, 2022 | $2.48B+19% | SEC ↗ |
| Q4 2020 | Nov 15, 2022 | $2.08B−2% | SEC ↗ |
| Q3 2020 | Nov 15, 2022 | $2.13B−2% | SEC ↗ |
| Q2 2020 | Nov 15, 2022 | $2.17B+42% | SEC ↗ |
| Q1 2020 | Nov 15, 2022 | $1.52B−8% | SEC ↗ |
| Q4 2019 | Nov 15, 2022 | $1.65B−50% | SEC ↗ |
| Q3 2019 | Nov 15, 2022 | $3.33B−37% | SEC ↗ |
| Q2 2019 | Nov 15, 2022 | $5.27B+172% | SEC ↗ |
| Q1 2019 | Nov 15, 2022 | $1.94B+129% | SEC ↗ |
| Q4 2018 | Nov 15, 2022 | $845.8M−19% | SEC ↗ |
| Q3 2018 | Nov 15, 2022 | $1.04B−12% | SEC ↗ |
| Q2 2018 | Nov 15, 2022 | $1.19B+94% | SEC ↗ |
| Q1 2018 | Nov 15, 2022 | $614.8M+67% | SEC ↗ |
| Q4 2017 | Nov 15, 2022 | $368.6M+7% | SEC ↗ |
| Q3 2017 | Nov 15, 2022 | $344.0M−1% | SEC ↗ |
| Q2 2017 | Nov 15, 2022 | $347.4M+10% | SEC ↗ |
| Q1 2017 | Nov 15, 2022 | $316.8M+8% | SEC ↗ |
| Q4 2016 | Nov 15, 2022 | $292.8M+6% | SEC ↗ |
| Q3 2016 | Nov 15, 2022 | $275.2M+31% | SEC ↗ |
| Q2 2016 | Nov 15, 2022 | $209.8M−14% | SEC ↗ |
| Q1 2016 | Nov 15, 2022 | $242.9M | SEC ↗ |